These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38893268)

  • 1. A Clinical Perspective on Plasma Cell Leukemia: A Single-Center Experience.
    Li AY; Kamangar F; Holtzman NG; Rapoport AP; Kocoglu MH; Atanackovic D; Badros AZ
    Cancers (Basel); 2024 Jun; 16(11):. PubMed ID: 38893268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
    Guan J; Ma J; Chen B
    Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Center Experience of Patients with Plasma Cell Leukemia in the Era of New Therapeutics.
    Dampmann M; Flossdorf S; Keyl J; Reinhardt HC; Hanoun C
    Acta Haematol; 2024 May; ():1-8. PubMed ID: 38763126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological and laboratory parameters of plasma cell leukemia among Indian population.
    Dubey H; Goel H; Verma S; Gupta S; Tanwar K; Rahul E; Kapoor G; Vasantharaman J; Ranjan A; Tanwar P; Chopra A
    Am J Blood Res; 2022; 12(6):190-195. PubMed ID: 36742277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia.
    Tessier C; LeBlanc R; Roy J; Trudel S; Côté J; Lalancette M; Boudreault JS; Lemieux-Blanchard É; Kaedbey R; Pavic M
    Cancer Med; 2024 Sep; 13(17):e70192. PubMed ID: 39225552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents.
    Talamo G; Dolloff NG; Sharma K; Zhu J; Malysz J
    Rare Tumors; 2012 Jun; 4(3):e39. PubMed ID: 23087795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells.
    Papadhimitriou SI; Terpos E; Liapis K; Pavlidis D; Marinakis T; Kastritis E; Dimopoulos MA; Tsitsilonis OE; Kostopoulos IV
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
    Wang H; Zhou H; Zhang Z; Geng C; Chen W
    Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
    An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
    Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
    Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
    Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
    Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M
    Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
    Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
    Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
    Katodritou E; Kastritis E; Dalampira D; Delimpasi S; Spanoudakis E; Labropoulou V; Ntanasis-Stathopoulos I; Gkioka AI; Giannakoulas N; Kanellias N; Papadopoulou T; Sevastoudi A; Michalis E; Papathanasiou M; Kotsopoulou M; Sioni A; Triantafyllou T; Daiou A; Papadatou M; Kyrtsonis MC; Pouli A; Kostopoulos I; Verrou E; Dimopoulos MA; Terpos E
    Am J Hematol; 2023 May; 98(5):730-738. PubMed ID: 36869876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic aberrations and survival in plasma cell leukemia.
    Tiedemann RE; Gonzalez-Paz N; Kyle RA; Santana-Davila R; Price-Troska T; Van Wier SA; Chng WJ; Ketterling RP; Gertz MA; Henderson K; Greipp PR; Dispenzieri A; Lacy MQ; Rajkumar SV; Bergsagel PL; Stewart AK; Fonseca R
    Leukemia; 2008 May; 22(5):1044-52. PubMed ID: 18216867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
    Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.
    Jin X; Jiang X; Li H; Shen K; Liu S; Chen M; Yang C; Han B; Zhuang J
    Acta Haematol; 2024 Apr; ():1-10. PubMed ID: 38626745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
    Lemieux C; Johnston LJ; Lowsky R; Muffly LS; Craig JK; Shiraz P; Rezvani A; Frank MJ; Weng WK; Meyer E; Shizuru J; Arai S; Negrin R; Miklos DB; Sidana S
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):e328-e332. PubMed ID: 32961371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical perspective on plasma cell leukemia; current status and future directions.
    Tuazon SA; Holmberg LA; Nadeem O; Richardson PG
    Blood Cancer J; 2021 Feb; 11(2):23. PubMed ID: 33563906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
    Lee Y; Yun J; Jeong D; Ryu S; Kwon SR; Yun H; Kim SM; Park JH; Lee DS
    Leuk Lymphoma; 2022 Feb; 63(2):385-394. PubMed ID: 34592901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.